Economic impact of the Taxus coronary stent: Implications for the Spanish healthcare system;Impacto económico del stent coronario Taxus: Implicaciones para el sistema sanitario español

Revista Espanola de Cardiologia

Volumn 59, Issue 9, 2006, Pages 889-896

  Russell, Stephen ^a,d   Antoñanzas, Fernando ^b   Mainar, Vicente ^c  

^a Premor Associates   (Spain)

^b UNIVERSITY OF LA RIOJA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d NONE   (Spain)

Author keywords

Coronary angioplasty; Cost effectiveness analysis; Restenosis; Stent

Indexed keywords

ADULT; ARTICLE; BUDGET; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; SPAIN;

EID: 33751005030     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13092796     Document Type: Article

References (29)

1. Alfonso F, Bermejo J, Segovia J. Estado actual de la revascularización coronaria. Rev Esp Cardiol. 2005;58:194-7.
2. Kastrati A, Mehilli A, Dirschinger J, Pache J, Ulm K, Schuhlen H, et al. Restenosis after coronary placement of various stent types. Am J Cardiol. 2001;87:34-9.
3. Betriu A, Masotti M, Serra A, Alonso J, Fernández-Aviles F, Gimeno F, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four year follow-up. J Am Coll Cardiol. 1999; 34:1498-506.
4. Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, López-Minguez JR, Moreu J, Calvo I, et al. Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial: Direct stenting of coronary arteries. Eur Heart J. 2002;23:633-40.
5. Popma JJ, Kuntz RE. Percutaneous coronary and valvular intervention. En: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia: WB Saunders; 2001. p.1364-405.
6. Lázaro P. Stents recubiertos de fármacos: eficacia, efectividad, eficiencia, y evidencia. Rev Esp Cardiol. 2004;57:608-12.
7. Macaya C. ¿Está justificado el uso sistemático de stents con fármacos? Argumentos en contra. Rev Esp Cardiol. 2004; 57:109-15.
8. Valdés M. ¿Está justificado el uso sistemático de stents con fármacos? Argumentos a favor. Rev Esp Cardiol. 2004;57:99-108.
9. Soikos SL. Base de datos de costes sanitarios. Barcelona, 2005.
10. Stone G, Ellis S, Cox D, Hermiller J, O'Shaughnessy C, Mann J, et al. One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: the TAXUS-IV trial. Circulation. 2004;109:1942-7.
11. Stone G, Ellis S, Cox D, Hermiller J, O'Shaughnessy C, Mann J, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31.
12. Stone GW. 2-year clinical results of the TAXUS-IV Trial. Presentado en et congreso TCT (Transcatheter Cardiovascular Therapeutics); Washington DC, 29 septiembre de 2004. Disponible en: http://www.bostonscientific.com/templatedata/imports/collateral/Coronary/ bsc_taxusIV_24month.pdf
13. Moussa I. Drug-eluting stents in diabetics. Presentado en el congreso TCT (Transcatheter Cardiovascular Therapeutics); Washington DC, 2004.
14. Permanyer C, Brotons C, Ribera A, Moral I, Cascant P, Alonso J, et al. Resultados clínicos y de calidad de vida de los pacientes tratados con angioplastia coronaria con balón o stent. Rev Esp Cardiol. 2001;54:597-606.
15. Muñoz M, Marrugat J. La prevención secundaria de la enfermedad coronaria es menos agresiva en los pacientes de más de 64 años. Rev Esp Cardiol. 2003;56:586-93.
16. Zamora A, Marrugat J. Pronóstico de los pacientes diabéticos con cardiopatía isquémica. Rev Esp Cardiol. 2002;55:751-62
17. López-Palop R, Moreu J, Fernández-Vázquez F, Hernández Antolín R. Registro Español de Hemodinámica y Cardiología Intervencionista. XIII Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2003). Rev Esp Cardiol. 2004;57:1076-89.
18. Mittmann N, Brown A, Jin Seung S, Coyle D, Cohen E, Brophy J, et al. Economic evaluation of drug eluting stents (technology report n.o 53). Ottowa: Canadian Coordinating Office for Health Technology Assessment; 2005.
19. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, Von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-70.
20. Ferreira A, Peter A, Salerno T, Bolooki H, De Marchena E. Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center. Ann Thorac Surg. 2003;7:485-9.
21. Kong D, Eisenstein E, Sketch M, Zidar J, Ryan T, Harrington R, et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J. 2004;147:449-56.
22. Thanikachalam M, Tehrani H, Salerno T. The clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization. En: Long-Term Healthcare 2004. London: Touch Briefings; 2004. p. 124-8.
23. Medical Virtual Market, S.L. Disponible en: http://www.concursossanitarios.com/Material-Sanitario.xsql
24. Cohen D, Taira D, Berezin R, Cox D, Morice M, Stone G, et al. Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction. Circulation. 2001;104:3039-45.
25. Birch S, Gafni A. The NICE approach to technology assessment: an economics perspective. Health Care Manag Sci 2004;7:35-41.
26. Van Hout H, Serruys P, Lemos P, Van den Brand M, Van Es G-A, Lindeboom W, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart. 2005;91:507-12.
27. Cohen D, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin R, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses. Circulation. 2004;110:508-14.
28. Oliva G, Espallargues M, Pons J. Stents recubiertos de fármacos antiproliferativos: revisión sistemática del beneficio y estimacíon del impacto presupuestario. Rev Esp Cardiol. 2004;57:617-28.
29. Kaiser C, Brunner-La Rocca H, Buser P, Bonetti P, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effektivitäts Trials (BASKET) Lancet. 2005;336:921-9.